Prospective analysis shows olfactory dysfunction in cystic fibrosis linked to biological correlates, suggesting ongoing issues post-therapy.
Olfactory dysfunction (OD) is a frequent yet underrecognized manifestation of chronic rhinosinusitis (CRS) in cystic fibrosis (CF) (1). Despite widespread reports of OD in CF, the impact of CFTR modulator therapy on smell outcomes remains unclear. We conducted a prospective study to evaluate olfactory function changes in CF-related CRS patients, as defined by EPOS2020 (2), following 12 months of elexacaftor/tezacaftor/ivacaftor (ETI) therapy, exploring clinical and biological correlates.
No takes yet. Share an insight, caveat, or question.
Minzoni et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: